Ono Pharmaceutical

4528.TPhase 3

ono-pharma.co.jp

Ono Pharmaceutical Co., Ltd. is one of Japan's oldest and most established pharmaceutical companies with over 300 years of history. The company has evolved from traditional medicine to become a leader in oncology, particularly through its co-development of Opdivo with Bristol Myers Squibb, which has become one of the world's leading cancer immunotherapies. Ono maintains a strong focus on research and development with particular expertise in immunology, oncology, and CNS disorders, while expanding its presence in international markets.

Market Cap

$6.9B

Employees

3000-4000

Focus

Biotech

4528.T · Stock Price

USD 2349.50520.00 (-18.12%)

Historical price data

AI Company Overview

Technology Platform

Small molecule drug discovery and development platform with expertise in immunomodulation, oncology, and CNS disorders, supported by strategic partnerships for global commercialization.

Pipeline Snapshot

187

187 drugs in pipeline, 56 in Phase 3

Drug	Indication	Stage
Rivastigmine transdermal patch	Alzheimer's Disease	Approved
Sivelestat sodium hydrate + Sivelestat sodium hydrate	Acute Lung Injury	Approved
Abatacept + Placebo matching with Abatacept + Methotrexate	Rheumatoid Arthritis	Approved
ONO-4538 + Placebo	Gastric Cancer	Phase 3
Ipilimumab + Oxaliplatin + Leucovorin + Fluorouracil + Irinotecan + Bevacizumab ...	Metastatic Colorectal Cancer	Phase 3

Opportunities

Significant growth potential through Opdivo line extensions, international expansion, and development of next-generation immunooncology combinations.

The company's strong financial position enables strategic acquisitions and partnerships to expand pipeline and geographic reach.

Risk Factors

Primary risks include patent expiration for key products like Opdivo, intense competition in oncology markets, and dependence on partner relationships for international commercialization.

Clinical trial failures and regulatory setbacks could impact pipeline value and growth prospects.

Competitive Landscape

Ono competes with major pharmaceutical companies including Bristol Myers Squibb, Merck, and Roche in oncology, while facing competition from AbbVie and Pfizer in hematology and immunology. The company differentiates through its strong Japanese market presence and successful immunooncology partnerships.

Publications

Patents

Pipeline

187